Highlight
- New-onset atrial fibrillation (AF) incidence within one year post-CABG is nearly 48%, significantly higher than previous reports.
- The burden of AF episodes detected is remarkably low, especially beyond 30 days after surgery.
- Findings suggest current guidelines recommending 60 days of oral anticoagulation after new-onset AF post-CABG may warrant reconsideration.
- Long-term continuous ECG monitoring with insertable cardiac monitors provides critical insights into AF dynamics following cardiac surgery.
Study Background
Atrial fibrillation is a common complication following coronary artery bypass grafting (CABG), often considered transient but associated with increased risks of stroke and other adverse outcomes. Current North American guidelines recommend a moderate-strength (Class 2a) approach of administering oral anticoagulation for 60 days in patients with new-onset AF after CABG. This recommendation, however, is based primarily on nonrandomized studies with limited comprehensive rhythm monitoring. The true incidence and temporal burden of AF in this population remain uncertain, posing a challenge in balancing thromboembolic risk and bleeding from anticoagulation therapy.
Study Design
This prospective, multicenter cohort study was conducted across two academic cardiac surgery centers in Germany, enrolling 198 patients undergoing CABG for three-vessel or left main coronary artery disease without any prior arrhythmia history. From November 2019 to November 2023, subjects received an implantable cardiac monitor at the time of surgery, enabling continuous electrocardiographic monitoring throughout one year postoperatively.
The primary endpoint was the cumulative incidence of new-onset atrial fibrillation detected within one year. Secondary endpoints included AF burden quantified by duration and frequency and clinical outcomes related to AF episodes.
Key Findings
From 1217 screened individuals, 198 were enrolled with a mean age of 66 years and male predominance (87.4%). Over one year, 95 patients (48%; 95% confidence interval [CI], 41%–55%) developed new-onset AF detected via continuous monitors. This incidence exceeds previous literature estimates, which generally report lower rates based on intermittent or in-hospital monitoring.
Despite this high incidence, AF burden—a critical dimension reflecting duration and potential clinical impact—was remarkably low. Median AF burden for the year was 0.07% (interquartile range [IQR], 0.02%–0.23%), equating to a median of 370 minutes of detected AF. Notably, the AF burden was highest in the early postoperative period: Days 1–7 had a median burden of 3.65% (IQR, 0.95%–9.09%) or approximately 368 minutes; days 8–30 markedly decreased to 0.04% (IQR, 0%–1.21%); and beyond day 31 nearly zero (median 0%, IQR, 0%–0.0003%), equivalent to no sustained AF episodes.
Furthermore, only three patients experienced an AF episode longer than 24 hours after hospital discharge, underscoring the limited duration and likely transient nature of post-CABG AF episodes.
Expert Commentary
These findings prompt a critical reassessment of the prevailing paradigm. Although new-onset AF is more common than previously appreciated when assessed through continuous long-term monitoring, the very low AF burden suggests limited clinical sequelae for the majority of affected patients. This raises questions regarding the universal implementation of anticoagulation beyond the acute postoperative period and highlights the importance of individualized risk stratification.
The biological plausibility aligns with perioperative stress, inflammation, and autonomic imbalance contributing to transient arrhythmogenic triggers rather than persistent atrial substrate changes post-CABG. This contrasts with chronic AF populations where AF burden correlates more strongly with thromboembolic risk.
There remain important limitations. The cohort was predominantly male and with specific coronary disease patterns, potentially limiting generalizability. Also, while continuous monitoring captures arrhythmia episodes with high fidelity, clinical outcome correlations such as stroke incidence require larger confirmatory studies.
Conclusion
This study significantly advances understanding of AF dynamics after CABG, demonstrating a substantially higher incidence of new-onset arrhythmia but with very low overall burden after the initial postoperative phase. These data challenge the contemporary guideline recommendation endorsing 60 days of oral anticoagulation, emphasizing the need for personalized therapeutic strategies grounded on arrhythmia burden and individual stroke risk rather than incidence alone.
Future research should prioritize randomized trials assessing the net clinical benefit of varying anticoagulation durations guided by continuous rhythm monitoring post-CABG. Such precision medicine approaches may optimize outcomes while minimizing unnecessary anticoagulation and associated risks.
References
Herrmann FEM, Jeppsson A, Kirov H, et al. Long-Term Continuous Monitoring of New-Onset Atrial Fibrillation After Coronary Artery Bypass Grafting. JAMA. 2025 Oct 9. doi:10.1001/jama.2025.14891. Epub ahead of print. PMID: 41065638.
January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update on Atrial Fibrillation Management: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2019;140(2):e125-e151.
Wyse DG, Waldo AL, DiMarco JP, et al. A Trial of Anticoagulation Guided by Continuous Rhythm Monitoring in Patients with Implantable Devices (IMPACT Trial). J Am Coll Cardiol. 2014;64(9):913-917.